367 related articles for article (PubMed ID: 16040567)
1. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives.
Leighton JK
Int J Toxicol; 2005; 24(3):153-5. PubMed ID: 16040567
[TBL] [Abstract][Full Text] [Related]
2. Applications of emerging technologies in toxicology and safety assessment.
Reynolds VL
Int J Toxicol; 2005; 24(3):135-7. PubMed ID: 16040564
[TBL] [Abstract][Full Text] [Related]
3. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
Jacobs A
Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
[TBL] [Abstract][Full Text] [Related]
4. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology.
Heijne WH; Kienhuis AS; van Ommen B; Stierum RH; Groten JP
Expert Rev Proteomics; 2005 Oct; 2(5):767-80. PubMed ID: 16209655
[TBL] [Abstract][Full Text] [Related]
5. The Japanese toxicogenomics project: application of toxicogenomics.
Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
[TBL] [Abstract][Full Text] [Related]
6. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
[TBL] [Abstract][Full Text] [Related]
7. Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview.
Chhabra RS; Bucher JR; Wolfe M; Portier C
Int J Hyg Environ Health; 2003 Aug; 206(4-5):437-45. PubMed ID: 12971699
[TBL] [Abstract][Full Text] [Related]
8. Toxicogenomics in predictive toxicology in drug development.
Suter L; Babiss LE; Wheeldon EB
Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
[TBL] [Abstract][Full Text] [Related]
9. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
Yang Y; Blomme EA; Waring JF
Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
[TBL] [Abstract][Full Text] [Related]
10. Applications of toxicogenomics to nonclinical drug development: regulatory science considerations.
Sistare FD; Degeorge JJ
Methods Mol Biol; 2008; 460():239-61. PubMed ID: 18449491
[TBL] [Abstract][Full Text] [Related]
11. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States.
Wu KM; Ghantous H; Birnkrant DB
Food Chem Toxicol; 2008 Aug; 46(8):2606-10. PubMed ID: 18614266
[TBL] [Abstract][Full Text] [Related]
12. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
13. From alternative methods to a new toxicology.
Hartung T
Eur J Pharm Biopharm; 2011 Apr; 77(3):338-49. PubMed ID: 21195172
[TBL] [Abstract][Full Text] [Related]
14. Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation.
Afshari CA; Nuwaysir EF; Barrett JC
Cancer Res; 1999 Oct; 59(19):4759-60. PubMed ID: 10519378
[TBL] [Abstract][Full Text] [Related]
15. Safety pharmacology investigations in toxicology studies: an industry survey.
Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
[TBL] [Abstract][Full Text] [Related]
16. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
17. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
Stevens JL
Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
[TBL] [Abstract][Full Text] [Related]
18. Application of genomics in preclinical drug safety evaluation.
Lord PG; Nie A; McMillian M
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
